Coya Therapeutics, Inc. SEC filings COYA
Coya Therapeutics, Inc. has 230 filings in SEC EDGAR's recent list, going back to Jan 5, 2021. Its latest annual report, Form ARS, was filed on May 13, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 14, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B5 | Prospectus supplement | May 12, 2026 | — |
| 424B3 | Prospectus | Mar 20, 2026 | — |
| S-3 | Shelf registration | Mar 16, 2026 | — |
| 424B5 | Prospectus supplement | Oct 27, 2025 | — |
| 424B5 | Prospectus supplement | Oct 23, 2025 | — |
| 424B7 | Filing | Aug 19, 2025 | — |
| S-3 | Shelf registration | Aug 12, 2025 | — |
| S-8 | Employee stock plan registration | Jan 30, 2025 | — |
| 424B3 | Prospectus | Nov 29, 2024 | — |
| S-3 | Shelf registration | Nov 20, 2024 | — |
| 424B3 | Prospectus | Jun 24, 2024 | — |
| S-3 | Shelf registration | Jun 14, 2024 | — |
| 424B3 | Prospectus | Jan 16, 2024 | — |
| S-3 | Shelf registration | Jan 4, 2024 | — |
| 424B4 | Prospectus | May 12, 2023 | — |
| POS AM | Filing | May 8, 2023 | — |
| S-8 | Employee stock plan registration | Apr 14, 2023 | — |
| 424B4 | Prospectus | Dec 30, 2022 | — |
| S-1/A | Amended registration statement | Dec 13, 2022 | — |
| FWP | Free writing prospectus | Dec 6, 2022 | — |
| S-1/A | Amended registration statement | Dec 5, 2022 | — |
| S-1 | Registration statement | Nov 18, 2022 | — |
Showing 22 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- COYA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1835022
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.